Adaptive Biotechnologies

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADPT and other ETFs, options, and stocks.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.

CEO

Chad Robins

CEOChad Robins

Employees

624

Employees624

Headquarters

Seattle, Washington

HeadquartersSeattle, Washington

Founded

2009

Founded2009

Employees

624

Employees624

ADPT Key Statistics

Market cap

2.81B

Market cap2.81B

Price-Earnings ratio

-53.54

Price-Earnings ratio-53.54

Dividend yield

—

Dividend yield—

Average volume

4.47M

Average volume4.47M

High today

$17.57

High today$17.57

Low today

$16.88

Low today$16.88

Open price

$17.00

Open price$17.00

Volume

3.88M

Volume3.88M

52 Week high

$20.76

52 Week high$20.76

52 Week low

$9.96

52 Week low$9.96

Stock Snapshot

With a market cap of 2.81B, Adaptive Biotechnologies(ADPT) trades at $17.52. The stock has a price-to-earnings ratio of -53.54.

During the trading session on 2026-06-19, Adaptive Biotechnologies(ADPT) shares reached a daily high of $17.57 and a low of $16.88. At a current price of $17.52, the stock is +3.8% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 3.88M, compared to an average daily volume of 4.47M.

Over the past 52 weeks, Adaptive Biotechnologies(ADPT) stock has traded between a high of $20.76 and a low of $9.96.

ADPT News

Benzinga 2d

Adaptive Biotechnologies Business Separation May Unlock Greater Value - Benzinga

...

TipRanks 3d

Adaptive Biotechnologies prices $300M convertible senior note offering

Adaptive Biotechnologies (ADPT) “announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 in a p...

Nasdaq 3d

Adaptive Biotechnologies Prices Upsized $300 Mln Sr. Notes Offering

(RTTNews) - Adaptive Biotechnologies Corporation (ADPT) on Wednesday said it has priced an upsized private offering of $300 million of 0% convertible senior not...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More ADPT News

Simply Wall St 3d

MRD Spinoff And $250 Million Convertible Notes Could Be A Game Changer For Adaptive Biotechnologies

Adaptive Biotechnologies recently completed a US$250,000,000 private offering of unsecured, senior, callable convertible notes due July 1, 2031, while also outl...

TipRanks 4d

Adaptive Biotechnologies Plans MRD and Immune Medicine Split

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

The Motley Fool 5d

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?

Francis Lo, Chief People Officer of Adaptive Biotechnologies (ADPT 6.22%), reported the sale of 39,741 shares of Common Stock for a transaction value of approxi...

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.